Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Apr 16 2010

Sunlight Research™ – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape.  Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.  

The Report evaluates 911 issued U.S. patents relating to stem cell technologies.  The stem cell patents have been categorized by stem cell type or origin and by the therapeutic methods contemplated in the patent claims for treating diseases.  The Report includes patents from over 349 assignees, including major pharmaceutical companies, academic research institutions and individual inventors.

Daniel A. Halpern, President of Sunlight Research, observed, "Certain stem cell therapies, especially those involving adult derived stem cells, are now increasingly ready for prime time, demonstrating clinical efficacy and progressing through clinical trials.  This is happening while the pharmaceutical industry is searching for new blockbuster opportunities.  Pfizer, Genzyme, Novo Nordisk, Johnson & Johnson, GlaxoSmithKline, Novartis and Roche, among others, have all made significant investments in regenerative medicine in the past few years. Understanding the intellectual property landscape and the specific strengths of individual patents is critical for those competing in this space."  Halpern added that "Industry professionals involved in patents, licensing, business development, investment analysis and others interested in the evolving stem cell therapy sector or those concerned about patent infringement risk and competitive threats in this field will find this to be a valuable resource."

Webinar April 28, 2010:

Sunlight's Stem Cell Patent Report, delivered in PDF and Excel formats, analyzes each independent claim of each patent relevant to one or more of 22 technical categories.  The Report, together with previously released reports focused on the U.S. patent portfolio of Osiris Therapeutics, and Amgen's U.S. patent portfolio relating to EPO, will be covered in a webinar to be held April 28, 2010 at 12:00pm CDT.  Register here:  https://www2.gotomeeting.com/register/907405514

BIO International Convention:

Sunlight, the BIO International Convention and the Association of University Technology Managers (AUTM) are co-sponsors of the BIO Technology Transfer Symposium to be held 2:00-5:00pm CDT, May 4, 2010.  Sunlight will also co-sponsor the BIO IP Counsel's Reception 6:30-8:00pm CDT, May 4, 2010.  Both of these events will take place during the BIO International Convention to be held at McCormick Place in Chicago, Illinois, May 3-6, 2010.

Convention attendees are also invited to visit Sunlight's booth P-12 in the BIOPark section of the main Exhibition Hall.  Sunlight will demonstrate how to use its claims-level analyses as cost-effective decision support tools to address stem cells, follow-on biologics and other life sciences sectors, in the BIOPark Theatre at 4:00pm CDT on Wednesday, May 5, 2010.